NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · GTH · USD
Stock price, earnings
Quote as of Mar 28, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Genetron Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genetron Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genetron Holdings Limited (GTH) is a precision oncology company that specializes in cancer molecular profiling, utilizing advanced molecular biology and data science to enhance cancer treatment. The company delivers a range of services, including diagnosis, monitoring, and early screening, primarily through its proprietary laboratory-developed tests. Its product offerings encompass a variety of in-vitro diagnostic (IVD) solutions. These include the 8-gene lung cancer assay, an IVD product for lung cancer detection; the Genetron 3D biochip reading instrument; and the Genetron S5, a semiconductor-based next-generation sequencing (NGS) system that identifies nucleotides by detecting pH changes. Other key products are the Genetron Chef System, the production-scale Genetron S2000 sequencing platform, and Onco PanScan, a genomic profiling service for diverse solid tumors. Moreover, Genetron provides specialized assays such as the IDH1 and TERT gene assays for glioma, a fundamental thyroid assay for thyroid tumors, a platelet-derived growth factor receptor alpha assay for GIST cancer, and HCCscan, a qPCR-based assay designed to detect hepatocellular carcinoma. Beyond its direct services and products, the company offers genomics research and clinical development services, often in collaboration with biopharmaceutical companies globally. Genetron has also established a strategic partnership with JD Health to develop holistic solutions for comprehensive cancer management. The company was founded in 2015 and has its headquarters in Beijing, People's Republic of China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.39 |
| $21.72M-0.03% vs estimate |
| Q1 2021 | May 24, 2021 | -$0.57+12.31% vs estimate | $14.02M-84.31% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$2.18+$0.02 (+0.93%)
Pardes Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
$1.54-$0.02 (-1.28%)
NGM Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.16% below the high.
$2.23+$0.04 (+1.83%)
Paratek Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.9% below the high.
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
$0.77$0.00 (0.0%)
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.69% below the high.
